Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema

PHASE2CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

January 3, 2019

Primary Completion Date

April 29, 2020

Study Completion Date

April 29, 2020

Conditions
Chronic Hand Dermatitis
Interventions
DRUG

ASN002

Daily dose of ASN002 for 32 weeks

DRUG

Placebo Oral Tablet

Daily dose of Placebo Oral Tablet for 16 weeks

Trial Locations (23)

21030

Maryland Laser Skin and Vein, Hunt Valley

23502

Virginia Clinical Research, Inc., Norfolk

33016

Sweet Hope Research Specialty, Inc, Hialeah

33174

RM Medical Research, Inc., Miami

36207

Pinnacle Research Group, LLC, Anniston

40241

Dermatology Specialists Research, Louisville

43209

Dermatologists of Greater Colombus, Bexley

46256

Dawes Fretzin Clinical Research Group, Indianapolis

48059

BTC Network, Fort Gratiot

55432

Minnesota Clinical Research Center, Fridley

70115

DelRicht Research, New Orleans

73112

Lynn Health Science Institute, Oklahoma City

SimcoDerm Medical and Surgical Dermatology Centre, Barrie

78213

Progressive Clinical Research, San Antonio

83713

Advanced Clinical Research, Boise

90045

Dermatology Research Associates, Los Angeles

99202

Dermatology Specialists of Spokane, Spokane

03801

ActivMed Practices and Research, Inc., Portsmouth

N6H5L5

Wei Jing Loo Medicine Professional Corp., London

L3P1X2

Lynderm Research Inc., Markham

M4W2N2

G. Daniel Schachter Medicine Professional, Toronto

H2K4L5

Innovaderm Research, Inc., Montreal

G1V4X7

Centre de Recherche Dermatologique du Quebec metropolitain, Québec

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Asana BioSciences

INDUSTRY